Comparative Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes

Comparative Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes

Background Clinical trials showed that glucagon‐like peptide‐1 receptor agonist (GLP1‐RA) significantly improved the control of diabetes and reduced body weight compared with dipeptidyl peptidase 4 inhibitor (DPP‐4i). However, it is unclear whether GLP1‐RA is effective compared with DPP‐4i in patien...

Full description

Saved in:
Bibliographic Details
Main Authors: Takefumi Kishimori, Takao Kato, Atsuyuki Wada, Akira Tani, Ryosuke Yamaji, Jumpei Koike, Yoshihiro Iwasaki, Takehiro Matsumoto, Takafumi Yagi, Masaharu Okada
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
dipeptidyl peptidase 4 inhibitor
glucagon‐like peptide‐1 receptor agonist
heart failure
type 2 diabetes
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.037510
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.124.037510

Similar Items